NO20052960L - Anvendelse av dokosahekasensyre som aktivt stoff til behandling av lipodystrofi - Google Patents

Anvendelse av dokosahekasensyre som aktivt stoff til behandling av lipodystrofi

Info

Publication number
NO20052960L
NO20052960L NO20052960A NO20052960A NO20052960L NO 20052960 L NO20052960 L NO 20052960L NO 20052960 A NO20052960 A NO 20052960A NO 20052960 A NO20052960 A NO 20052960A NO 20052960 L NO20052960 L NO 20052960L
Authority
NO
Norway
Prior art keywords
lipodystrophy
treatment
docosahexaenoic acid
active substance
hiv
Prior art date
Application number
NO20052960A
Other languages
English (en)
Inventor
Juan Carlos Domingo Pedrol
Pere Pedrol
Original Assignee
Proyecto Empresariel Brudy Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Empresariel Brudy Sl filed Critical Proyecto Empresariel Brudy Sl
Publication of NO20052960L publication Critical patent/NO20052960L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Det er beskrevet anvendelse av et ekstrakt av dyre-, plante- eller mikroorganismeprodusert opprinnelse som omfatter dokosaheksaensyre som aktivt stoff til fremstilling av et legemiddel for behandling av lipodystrofi i et pattedyr. Nevnte behandling er effektiv og overvinner ulemper ved foreliggende lipodystrofibehandlinger hos HIV-infiserte pasienter.
NO20052960A 2002-12-05 2005-06-16 Anvendelse av dokosahekasensyre som aktivt stoff til behandling av lipodystrofi NO20052960L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200202963A ES2209658B1 (es) 2002-12-05 2002-12-05 Utilizacion del acido docosahexaenoico como principio activo para el tratamiento de la lipodistrofia.
PCT/IB2003/005673 WO2004050077A1 (en) 2002-12-05 2003-12-01 Use of docosahexanoic acid as active substance for the treatment of lipodystrophy

Publications (1)

Publication Number Publication Date
NO20052960L true NO20052960L (no) 2005-06-16

Family

ID=32405973

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052960A NO20052960L (no) 2002-12-05 2005-06-16 Anvendelse av dokosahekasensyre som aktivt stoff til behandling av lipodystrofi

Country Status (24)

Country Link
US (1) US8202906B2 (no)
EP (1) EP1585513B1 (no)
JP (1) JP2006511514A (no)
KR (1) KR100906086B1 (no)
CN (1) CN100355421C (no)
AT (1) ATE326959T1 (no)
AU (1) AU2003302679B2 (no)
BR (1) BR0316973A (no)
CA (1) CA2506993C (no)
CY (1) CY1105205T1 (no)
DE (1) DE60305534T2 (no)
DK (1) DK1585513T3 (no)
EA (1) EA009711B1 (no)
ES (2) ES2209658B1 (no)
IL (1) IL168766A (no)
IS (1) IS2384B (no)
MX (1) MXPA05005911A (no)
NO (1) NO20052960L (no)
NZ (1) NZ540262A (no)
PL (1) PL377563A1 (no)
PT (1) PT1585513E (no)
UA (1) UA79650C2 (no)
WO (1) WO2004050077A1 (no)
ZA (1) ZA200503872B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1656934A1 (en) * 2004-11-12 2006-05-17 Cognis IP Management GmbH Use of physiologically active fatty acids for treating lipodystrophy
ES2277557B1 (es) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
JP5207342B2 (ja) * 2007-02-26 2013-06-12 独立行政法人産業技術総合研究所 炎症性サイトカイン産生抑制剤
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
JP5570999B2 (ja) * 2008-01-03 2014-08-13 ユニベルシテ デ―マルセイユ 抗ｈｉｖ治療の際に使用される組成物
CN110339187B (zh) * 2019-07-30 2021-12-14 中国医学科学院病原生物学研究所 缓解寨卡病毒感染相关的新生儿小头症的药物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3901048A1 (de) * 1989-01-14 1990-07-19 Chimicasa Gmbh Antikachectikum
US5089268A (en) * 1990-05-02 1992-02-18 Katz David P Egg phosphatide lipid emulsions altered for a specific therapeutic fatty acid composition
DE4017979A1 (de) * 1990-06-05 1991-12-12 Meyer Lucas Gmbh & Co Lipid- bzw. phospholipid-zusammensetzungen sowie diese enthaltendes mittel zur behandlung von erkrankungen sowie auf die zellmembrane zurueckzufuehrende stoerungen
JP3092180B2 (ja) * 1991-02-27 2000-09-25 日本油脂株式会社 低密度リポ蛋白受容体活性化剤
GB9116054D0 (en) * 1991-07-24 1991-09-11 Efamol Holdings Preparation of fatty acid medicaments
JPH0923817A (ja) * 1995-07-07 1997-01-28 Nisshin Oil Mills Ltd:The 油脂含有飲食物
FR2749133A1 (fr) * 1996-06-04 1997-12-05 Pierre Moreau Obtention d'oeufs specifiquement enrichis en acide cervonique (acide docosahexaenoique ou dha). applications alimentaires, therapeutiques et industrielles de ces oeufs et de leurs extraits lipidiques
FR2790758A1 (fr) * 1999-03-09 2000-09-15 Commissariat Energie Atomique Solubilisation d'acides gras polyinsatures et de leurs derives par formation de complexes d'inclusion avec une cyclodextrine et leur utilisation dans des compositions pharmaceutiques, cosmetiques ou alimentaires
CA2290885A1 (fr) * 1999-12-02 2001-06-02 Universite De Sherbrooke Methode pour la transformation des tissus du loup marin
EP1121928B1 (en) * 2000-01-31 2008-01-23 Härting S.A. Compositions containing phytosterol and policosanol esters of fatty acids for reducing blood cholesterol and triglycerides
JP2001314170A (ja) * 2000-05-09 2001-11-13 Toyo Shinyaku:Kk 麦若葉由来の素材を含む抗コレステロール食品
ATE305810T1 (de) * 2000-05-22 2005-10-15 Pro Aparts Investimentos E Con Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält
US8017651B2 (en) * 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia

Also Published As

Publication number Publication date
CY1105205T1 (el) 2010-03-03
ES2265607T3 (es) 2007-02-16
IS2384B (is) 2008-07-15
UA79650C2 (en) 2007-07-10
EP1585513A1 (en) 2005-10-19
EP1585513B1 (en) 2006-05-24
MXPA05005911A (es) 2005-08-29
PT1585513E (pt) 2006-10-31
ES2209658A1 (es) 2004-06-16
CA2506993C (en) 2010-04-13
CN100355421C (zh) 2007-12-19
ATE326959T1 (de) 2006-06-15
AU2003302679B2 (en) 2009-01-15
EA009711B1 (ru) 2008-02-28
JP2006511514A (ja) 2006-04-06
ZA200503872B (en) 2006-08-30
CN1720039A (zh) 2006-01-11
KR100906086B1 (ko) 2009-07-06
DE60305534D1 (de) 2006-06-29
PL377563A1 (pl) 2006-02-06
US20060178436A1 (en) 2006-08-10
CA2506993A1 (en) 2004-06-17
KR20050085313A (ko) 2005-08-29
US8202906B2 (en) 2012-06-19
IL168766A (en) 2009-11-18
ES2209658B1 (es) 2005-10-01
IS7912A (is) 2005-06-23
DE60305534T2 (de) 2007-05-16
EA200500765A1 (ru) 2005-12-29
WO2004050077A1 (en) 2004-06-17
NZ540262A (en) 2006-11-30
DK1585513T3 (da) 2006-09-18
BR0316973A (pt) 2005-10-25
AU2003302679A1 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
NO20052960L (no) Anvendelse av dokosahekasensyre som aktivt stoff til behandling av lipodystrofi
NO20064186L (no) Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod
MY144292A (en) Method of reducing oral tissue inflammation using magnolia extract
DE69930259D1 (de) Zusammensetzungen zur anwendung von entzündungshemmenden, insbesondere antiseptischen und/oder wundheilenden wirkstoffen im oberen atemwegtrakt und/oder ohr
ATE281839T1 (de) Behandlung des kongestiven herzversagens durch vorbehandeltes autologes blut
BR0212252A (pt) Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero
NO20035743D0 (no) Substituerte oksazolindinoner for kombinasjonsterapi
ATE332136T1 (de) Mittel, wie nikotinamide oder cadpr zur behandlung von hautkrankheiten
BRPI0313148B8 (pt) formulações sólidas matriciais de lamotrigina contendo revestimento externo e perfuração em tal revestimento
NO20004282L (no) Matriksproteinpreparater for sÕrheling
ATE318610T1 (de) Orale zusammensetzungen zur behandlung von kopfhauterkrankungen
ATE407690T1 (de) Topische pharmazeutische zusammensetzungen enthaltend aktive natürliche bestandteile zur verhütung und behandlung von mucosalen entzündungprozessen
DK1677806T3 (da) Sammensætninger til behandling af akut og overbelastningsforårsaget forstuvning og forstrækning ved anvendelse af hyaluronsyre
HUP0304077A2 (hu) A bőr öregedése elleni gyógyászati és kozmetikai készítmények
UY26474A1 (es) Inhibidores de aminotransferasa dependiente de aminoácidos de cadena ramificada, y su uso en el tratamiento de la retinopatía diabética.
PT1414467E (pt) Tratamento topico da mastalgia
HK1037980A1 (en) Use of selegiline or desmethylselegiline for the manufacture of a medicament for treating wounds, burns or photodamage.
DE60305068D1 (de) Behandlung von mastalgie mit4-hydroxy-tamoxifen
DK1343472T3 (da) Thixotropisk næsespray
MXPA05010416A (es) Combinacion de substancias activas de aceites minerales que contienen acidos grasos (3 con extractos vegetales que contengan polifenoles y su uso.
EP1557163A4 (en) THERAPEUTIC AGENT FOR CONTRACTING MUCOSAL TISSUE, METHOD FOR TREATING DISEASES ASSOCIATED WITH MUCOSAL TISSUES, INJECTOR AND THERAPEUTIC KIT
Rinwa et al. Panax quinquefolium involves nitric oxide pathway in olfactory bulbectomy rat model
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
NO20064196L (no) Utvortes preparat for behandling av smertefulle hudskader
HUP0203321A2 (hu) (6-Metoxi-2-naftil)-ecetsav prodrug készítmények gyulladás kezelésére

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application